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The clXxts 01’ a novel cyclic pcnupcptidc (BQ-123). an cndothelin (ET) antagonist sclcctivc for the ET,, rcccptor subtype, on phosphoinositidc 
breakdown and DNA synthesis stimulated by ET-I wrrc studied in cultured rot vascular smooth muscle cells (VSMC). BQ-123 compcGtivcly 
inhibited the binding or [“‘l]ET-I to VSMC with the apparent Ki of 4 x IO-” M. BQ-123 dose-dupendcntly inhibited formation of inositol-l.J,S- 
trisphosphate and [“Hlthymidinc uptukc stimulated by ET- I. Thcsc data suggest that the ET-I-induced DNA synthesis in VSMC is mainly medialcd 
by ET,, rcccptor subtype. 
Endothclin-I: Rcccptor antagonist; lnosilol Irisphosphate; DNA synthesis: Vuscular smooth muscle cell 
1. INTRODUCTION 
Endothelin- I (ET-I) is a novel 21-residue vasocon- 
strictor pcptidc originally isolated from the supernatant 
of cultured porcine endothelial cells [I]. Subsequent 
cDNA cloning of the human genomic library revealed 
three ET isopeptides. ET-I, ET-2 and ET-3; these three 
isopeptides have different pharmacological profiles of 
pressor/vasoconstrictor activities, suggesting the heter- 
ogeneity of ET receptors 121. Two distinct ET receptor 
subtypes have recently been cloned and sequenced [3,4]; 
one subtype shows selective affinity for ET-I and ET-2 
(ET,,), whereas the other subtype shows non-selective 
affinity for three isopeptides (ETJ. These receptors be- 
long to the superfamily of G-protein-coupled receptors. 
In cultured rat vascular smooth musclecells (VSMC) we 
have shown that ET-I and ET-2 interact wiih ET recep- 
tors with almost the same affinity, while ET-3 had a far 
lower binding affinity, suggesting that VSMCs predom- 
inantly express ETA receptors [5]. In addition to its role 
as a vasoconstrictor, ET-I has been shown to stimulate 
DNA synthesis of VSMC, expression of proto-onco- 
genes (c#s, c-IIZJW), and increase in cell number [6-81, 
suggesting its possible involvement in the development 
of atherosclerotic vascular lesion. 
Recently, a novel cyclic pentapeptide @E-182578), 
cyclo(-D-Glu-L-Ala-allo-D-Ile-L-Leu-D-Trp-), isolated 
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from the fermentation products of SWC~~O~IJWS ntisu- 
kiensis, has been shown to be a selective ETA antagonist 
[9]. Very recently a more potent ET,, antagonist analog 
(BQ-I 23), cyclo(-D-Asp-L-Pro-DVal-L-Leu-D-Trp-), has 
been synthesized [IO]; BQ-123 is two orders of magni- 
tude more potent than BE-18257B in antagonizing ET- 
1 -induced vasoconstrictor/pressor actions. These re- 
ports prompted us to examine the effects of BQ-I23 on 
receptor binding activity, phosphoinositide breakdown 
and DNA synthesis timulated by ET-I in cultured rat 
VSMC. 
2. MATERIALS AND METHODS 
ET-l. ET-2 and ET-3 wcrc purchased from Pcptidc lnstitutc 
(Osaka, Japan). [12’I]ET-I (spcx act. 2.000 CiImmol) from Amcrsham 
inurnarional (Tokyo, Japan), and [“Hlthymidinc (SJXC. XI. 6.7 Gil 
mmol) rrom New England Nuclear (Boston, MA). DQ-I23 was syn- 
thcsized as rcairtly rcportcd [lo]. 
VSMCs were prcparcd from the thoracic aorta of I 5-week-old male 
Wistar rats by the explant method, and cultured in Dulbccco’s modi- 
ficd Eagle’s medium (DMEM) containing 10% Octal calf strum at 
37°C in a humidified atmosphere of 95% air-5% CO2 as previously 
described [I I]. The cells thus obtained showed the ‘hills-and-valleys’ 
growth characteristic or cultured VSMCs in vhro; the cxpxssion or 
20 kDa myosin light chain and its phosphorylation by angiotcnsin and 
vasoprcssinc have been reported [ 121. Subcultured VSMCs ( 1020th 
pdSSiigCS) wcrc used in the cnpcrimcnls. 
Confluent VSMCa (5 x IO’ cells) wcrc usually incubated with 6 pbl 
[‘2sl]ET-l at 37OC ror 60 min in Hanks’ balanced rnlt sohnion conuin- 
ing 0.1% bovine serum albumin, in the same manner 3s reported [ 14. 
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Specific binding was dctcrmincd by subtntctinl: non-specilic binding in 
the prrssncc of excess (IO-’ M) unlebeled ET-I from tolal bindinp. 
2.4. Mra,~llr~‘itI~‘t~I i/’ itrosirtrl-!.~.5-l~ispirosp8rrrc ([P,,) 
Conlluent VSMCs were incubated at 37°C for 30 s in Hanks’ bal- 
anced salt solution containing IO mM LiCI. Incubation was tcrmi- 
nated by the addition of prrchloric acid and IP,, wus mcasurcd by a 
rudiorcccptor assay kit (Du Pow Boslon. MA). 
DNA synthesis was assessed by incorporation of[“H]thymidine imo 
cells as orcviouslv dcscribcd 171. In brief. subconflulnt \‘ShlCs f3 x 
IO” cell;) that b&me quicsienl after replxement wilh serum-&e 
DMEM for 48 h, wcrc incubated whh or without ET-I for ?O h, allcr 
which I +i [lH]thymidine was added and further incubtitcd for 4 h. 
After compleGon, trichloroucelic acid-insoluble rndiouc\ivity wils 
measured in a liquid scintillation counter. 
3. RESULTS 
A competitive binding study using [“‘IlET-I as a 
radioligand to rat VSMC is shown in Fig. 1. ET-l and 
ET.2 equipotently inhibited the binding of [“51]ET-I, 
while ET-3 showed a far less potent inhibition than 
ET-l and ET-Z. BQ-123 also competitively inhibited 
[“‘IlET- binding to its receptor sites. The apparent 
inhibition constant (Ki) values for BQ-123, ET-I, ET-2 
and ET-3 were4.0 x 10m9 M, 1.0 x IO-‘” M. 1.3 x IO-‘” 
M and 7.7 x IO-* M, respectively. 
The effects of BQ-123 on ET- l-induced IP, formation 
in cultured rat VSMC are shown in Fig. 2. ET-l dose- 
dependently (30-9-10-’ M) stimulated IPJ formation, 
while BQ-123 (10m6 M) almost completely inhibited IPJ 
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Fig. I. Competitive binding ~f[‘~“l]ET-l to rat VSMC. ConRucnt cells 
(5 x 10’ cells/well) wcrc incubated with 6 pM [““IlET-I in the absence 
and the presence of BQ- I23 (e), ET-I (O), ET-2 (A) and ET-3 (0) in 
the indicated concemrations. Results are expressed as the psrcentilgc 
of specific binding in the absence of pcplides (6,): each point is the 
metin of three experiments. 
formation s:imu!ated by ET-I (IO-“-lo-’ M) (Fig. 2A), 
BQ-123 (l0-5-l0-h M) alone did not affect basal IPJ 
formation. BQ-123 dose-dependently (I O-'-l 0w5 M) in- 
hibited IP, formation maximally stimulated by ET-I 
(IO-’ M) with the approximate dose for half-maximal 
inhibition (IC,,) of 2 x IO-* M (Fig. 2B). 
The effects of BQ-123 on DNA synthesis timulated 
0 8 7 8 5 
- Log [X&123] M 
Fig, 2, ElTccts of BQ-I23 WI ET-l-induced IPJ formation in rdt VSMC. ConRuem cells (:! v IO” cells) were incubaled with various concenu-alions 
of ET-I in the absence (0) and the prescncc (3) of IO-” M BQ-I?3 (A), or with IO-’ M ET-I in the abscncc: and the presence of BQ-I23 in 
concentradons as indicated (B). Each point is the mean of thrc- samples and reprcscnrs the pcrcentagc LO the basal levels (8.3 rt O,? pmo!); bars 
show S.E.M. 
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Fig. 3, Effects of BQ-123 on ET-l-induced DNA synthesis in rat VSMC. Quiescent VSMCr (3 x IOs cells) were incubated with variousconcentrations 
of ET-I in the absence (0) ond the prcscncc (:j) or 10mh M BQ-123 (A), or with IO-” M ET-1 in the absence and the prescncc of BQI23 in 
concentrations as indicated (6). Edch point is the mean ol’four samples and rcprcscnts the percentage ofthc basal rH]thymidine uptake (15.6 + 0.8 
x IO1 dpm): bars show S.E.M. 
by ET-l in cultured rat VSMC are shown in Fig. 3. ET-1 
dose-dependently (10-‘“-10-7 M) stimulated [“HIthy- 
midine uptake in quiescent VSMCs; BQ-123 ( 10Nn M) 
shifted the dose-response curve to the right, while BQ- 
123 alone dit not affect basal [3H]thymidine uptake (Fig. 
3A), BQ-123 dose-dependently ( 1O-x-1O-5 M) inhibited 
DNA synthesis maximally stimulated by ET- I (IO-’ M) 
with the approximate I&, of 1 x IO-’ M (Fig. 3B). 
4. DISCUSSION 
The present study demonstrates for the first time that 
a novel ET,, receptor antagonist BQ-123 inhibits IP, 
formation and DNA synthesis timulated by ET-l in 
cultured rat VSMC. The present binding data are com- 
patible with our previous observation that cultured rat 
VSMCs possess predominantly ETA subtype receptors 
[Sj. In the present binding study BQ-123 competitively 
inhibited the binding of [‘251]ET-l to its vascular ecep- 
tor with high-affinity (Ki 4 x LOW9 M), indicating that 
BQ-123 is highly selective for vascular ET,, receptor 
subtype. Our results are in good agreement with those 
of porcine VSMC as recently reported [lo]. 
It has been shown that ET-1 stimulates phospholip 
ase c-mediated phosphoinositide breakdown in VSMC 
to generate IPJ, which in turn mobilizes intracellular 
Ca?+ from its storage sites [13,14]. The present study 
clearly demonstrates that BQ-!23 dose-dependently in- 
hibits IP2 formation stimulated by ET-l in cultured rat 
VSMC. The approximate I& (2 x 10-s M) of BQ-123 
for lPj formation appears almost comparable to its KS0 
(7.4 x lo-” M) for the ET-1 -induced vasoconstriction as 
recently reported [IO]. 
In addition to its potent vasoconstrictor effect, ET-l 
has been shown to stimulate DNA synthesis of rat 
VSMC in culture [6--81. In the present study, we have 
demonstrated that BQ-123 has an inhibitory effect on 
DNA synthesis induced by ET-1 in cultured rat VSMC, 
as characterized by the rightward shift of the dosc- 
response curve by BQ-I 23. However, the magnitude of 
the shift produced by lo-” M BQ-123 on the ET-I dose- 
response curve of DNA synthesis appears to be less 
potent than that of IPJ formation. Such discrepancy 
may be accounted for by the difference in the affinity 
of the receptors mediating the two responses for the 
antagonist. In fact, the present binding study showed 
that about 15% of specific binding of [“51]ET-1 to rat 
VSMC was not displaced by BQ-123 even at IO-” M. 
The same result was also observed in porcine VSMC 
membranes [lo]. Thus, it is probable that cultured rat 
VSMCs may possess mall amount of non-isopeptide- 
selective ETs receptors through which ET-l may also 
stimulate DNA synthesis. Alternatively, the difference 
in the magnitude of !he shifts by BQ-123 may be due to 
metabolism of the antagonist, altered biodistribution, 
and/or receptor modification, since it takes only 30 s for 
measurement of 1P3 but 24 h for measurement of DNA 
synthesis. Further study is needed to elucidate the mo- 
lecular interaction between receptor subtypes and their 
signal transduction systems in VSMC. 
It should be noted that circulating ET-1 levels were 
elevated in patients with atherosclerosis [15,16], impli- 
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eating the possible involvement of endogenous ET- 1 in 
the development of atherosclerotic vascular lesions, 
Thus, a selective ETA receptor antagonist (BQ-123) 
which inhibits the ET-l-induced phosphoinositide 
breakdown and DNA synthesis in rat VSMC will be a 
useful tool to know whether ET-1 has any pathophysi- 
ological role in the development of atherosclerotic vas- 
cular lesion, 
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